COVID-19 outcomes among vaccinated and unvaccinated patients receiving disease-modifying antirheumatic drugs and biologic therapies: a retrospective multihospital cohort study
Aug 2026· Clinical Rheumatology· Vol 45, pp. 5989 - 5997· 0 citations· 31 references
Medicine
TL;DR
COVID-19 vaccination was independently associated with a 37% reduction in hospital length of stay among immunosuppressed patients receiving DMARDs or biologics, supporting vaccination as a critical protective strategy in immunosuppressed populations.
OBJECTIVE
We aimed to assess the association between COVID-19 vaccination status and COVID-19-related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions.
METHODS
We conducted a retrospective cohort study using Na...
Lesley E. Jackson, A. J. Anzalone, K. Saag et al.· Arthritis & Rheumatology· 0 citations
A substantial benefit of vaccination for people on immunosuppressive therapy is shown, particularly after three vaccine doses and against severe outcomes, particularly after three vaccine doses and against severe outcomes.
E. Stadler, Shanchita R. Khan, K. M. Elias et al.· The Lancet Microbe· 0 citations
Background: Fatal COVID-19 cases continued to occur after the introduction of vaccination, particularly among older adults and individuals with chronic comorbidities. This study aimed to describe and compare the demographic and clinical characteristics of vaccinated and unvaccinated adults who died from COVID-19. Metho...
Yeşim Işler, Halil Kaya, Abdullah Furkan Ortabük et al.· Vaccines· 0 citations
While most ARD patients demonstrated a detectable response, gender appeared to influence antibody levels, with females exhibiting a weaker response, which is consistent with the literature suggesting that vaccine efficacy may be reduced in immunocompromised populations.
Reza Farrokhseresht, Hanieh Roghanian, H. Samimagham et al.· Acta Medica Iranica· 0 citations
Background Patients with inflammatory rheumatic diseases (IRDs) may be at increased risk for adverse COVID-19 outcomes because of immune dysregulation, comorbidities, and immunomodulatory treatments. However, the effects of specific rheumatic disease subsets, treatment patterns, and vaccine types remain incompletely un...
Feyza Ak, Zeynep Kaya· Frontiers in Public Health· 0 citations
Background: Immunocompromised patients are at heightened risk for severe COVID-19 and its complications. While vaccination is critical for this population, long-term adherence and the durability of vaccine-induced immunity remain significant public health concerns. This study aimed to evaluate the longitudinal serologi...
A. Sarcone, Maria Rosaria Deodato, A. De Pasquale et al.· Vaccines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
